347 related articles for article (PubMed ID: 23234470)
1. Off-label marketing and the First Amendment.
Boumil MM
N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
[No Abstract] [Full Text] [Related]
2. Prescriptions, privacy, and the First Amendment.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2011 May; 364(21):2053-5. PubMed ID: 21524208
[No Abstract] [Full Text] [Related]
3. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
4. Higher First Amendment hurdles for public health regulation.
Outterson K
N Engl J Med; 2011 Aug; 365(7):e13. PubMed ID: 21812665
[No Abstract] [Full Text] [Related]
5. Regulating Off-Label Promotion - A Critical Test.
Robertson C; Kesselheim AS
N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
[No Abstract] [Full Text] [Related]
6. Pharmaceutical promotion to physicians and First Amendment rights.
Kesselheim AS; Avorn J
N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
[No Abstract] [Full Text] [Related]
7. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
Roehr B
BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
[No Abstract] [Full Text] [Related]
8. Clinical trial transparency--antidote to weaker off-label-promotion rules?
Outterson K
N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
[No Abstract] [Full Text] [Related]
9. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
Hall RF; Sobotka E
Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
[No Abstract] [Full Text] [Related]
10. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
11. The future of off-label marketing regulations in the post-Sorrell era.
Iraggi J
Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
[No Abstract] [Full Text] [Related]
12. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
13. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
14. Off-label marketing: free speech or illegal promotion?
Silverman E
BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
[No Abstract] [Full Text] [Related]
15. Court rules that FDA cannot restrict off-label marketing.
Roehr B
BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
[No Abstract] [Full Text] [Related]
16. The limits of free speech.
Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
[No Abstract] [Full Text] [Related]
17. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
18. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
Rabinowitz DP
Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
[TBL] [Abstract][Full Text] [Related]
19. Smoking and the First Amendment.
Outterson K
N Engl J Med; 2011 Dec; 365(25):2351-3. PubMed ID: 22149735
[No Abstract] [Full Text] [Related]
20. Why doctors should worry about preemption.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
